PBRM1 and clear cell renal carcinoma: Notably, it was previously reported that mutation in PBRM1, a component of chromatin remodeling complex SWI/SNF-B, was associated with clinical benefit from ICB therapy for clear cell renal cell carcinoma [20,43].